Aducanumab
Aducanumab is a medication designed to treat Alzheimer's disease by targeting and removing amyloid plaques—abnormal protein clumps that build up in the brains of people with this condition. The goal is to slow down cognitive decline and potentially improve brain function in affected individuals. It is administered via intravenous infusion and was notable for being the first Alzheimer's drug approved by the FDA in nearly two decades, although its approval has sparked debate about its effectiveness and cost. Researchers continue to study its long-term impacts and ideal patient populations for treatment.
Additional Insights
-
Aducanumab is a medication designed to treat Alzheimer’s disease by targeting amyloid plaques in the brain, which are believed to contribute to the progression of the disease. It is a type of monoclonal antibody that helps the body remove these harmful protein aggregates. While Aducanumab has generated excitement for its potential to slow cognitive decline in some patients, it has also faced controversy regarding its effectiveness and approval process. It is typically administered through intravenous infusion, and patients should discuss potential benefits and risks with their healthcare providers.